Cancer treatment has evolved from traditional chemotherapy and radiation to the era of personalized or precision medicine. In this journey, diagnosis leads the way: genetic testing now plays a key role in guiding personalized treatment. It helps determine tumor subtypes, informs treatment selection, assesses hereditary risk, and predicts prognosis and recurrence.

NGS enables comprehensive testing in a single run. It is especially useful when tissue samples are limited or when complex mutations are involved, and today it is widely adopted in clinical practice.

Genecast OncoDuo Prime is a precision therapy test for patients with 20+ solid tumor types. It combines DNA and RNA-based NGS to detect 4 major genomic alterations—SNV, InDel, CNV, and fusions—providing information to guide treatment selection and prognosis.

The test also includes MSI analysis, offering evidence to support the use of immune checkpoint inhibitors and enabling more comprehensive, personalized cancer care.

Specifications